When the FBI Asks, Should Scientists Tell?

Working with dangerous pathogens soon may become a hazard to intellectual autonomy with new laws that widen federal scrutiny of university labs and other research centers, according to scientists and policymakers. Already the FBI has queried academic scientists about their use of anthrax and other biological materials. The U.S. Attorney General's office is also using criminal, immigration, and national security databases to determine whether people possessing, using or transferring such agents a

Written byWillie Schatz
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

A provision in the Bioterrorism Preparedness Act, (S. 1765), which the Senate passed Dec. 20, would allow the secretary of Health and Human Services (HHS) to establish new security restrictions for people possessing or transferring biological agents and toxins. Lawmakers also may codify new limitations on information exchange that have a significant impact on sharing and releasing information.

"The problem won't be regular FBI visits to universities," warns Ron Atlas, president-elect of the Washington, DC-based American Society of Microbiologists (ASM.) "It's going to be increased scrutiny by law enforcement of anyone doing dangerous pathogen research. That alone won't compromise intellectual freedom. But that combined with the public and political backlash certainly will."

Atlas cautions that new laws could severely affect researchers' working conditions so that few would work under the increased scrutiny. These laws compound the problems already faced by universities that have experienced FBI visits and queries, requiring many ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies